Patent ID: 7560230

Claim:
A method for determining whether pancreatic islet cell carcinoma in an individual patient is susceptible to treatment with an anti-neoplastic agent transported by a glucose transporter, wherein the anti-neoplastic agent comprises either a glucose moiety or a glucose analog moiety selected from the group consisting of D-(+)-2-deoxy-glucose, D-(+)-2-amino-2-deoxy-glucose, N-acetyl D-(+)-2-amino-2-deoxy-glucose, D-mannose, D-3-amino-3-deoxy-glucose, D-2-amino-2-deoxy-glucose, D-galactose, D-2-deoxy-D-galactose, D-4-amino-4-deoxy-galactose, D-2-amino-2-deoxy-galactose, and fructose, comprising the steps of: (a) obtaining a sample of the pancreatic islet cell carcinoma from the patient; (b) measuring the level of the glucose transporter in the sample; (c) comparing the measured level of the glucose transporter in the sample to the level of the glucose transporter in a sample of non-tumor pancreatic tissue; and (d) determining that the pancreatic islet cell carcinoma is susceptible to treatment with the anti-neoplastic agent if the measured level of the glucose transporter in the sample is greater than the level of the glucose transporter in the sample of non-tumor pancreatic tissue.